Tilmann Bochtler
Advanced in Leukemia

Tilmann Bochtler

Heidelberg, BW, DE 
Advanced in Leukemia
Heidelberg, BW, DE 
OverviewLocationsClinical Research

Overview

Tilmann Bochtler practices in Heidelberg, Germany. Bochtler is rated as an Advanced expert by MediFind in the treatment of Leukemia. Their top areas of expertise are Acute Myeloid Leukemia (AML), Primary Amyloidosis, Leukemia, Acute Promyelocytic Leukemia, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 60 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 22 articles and participated in 2 clinical trials in the study of Leukemia.

Locations

Heidelberg, BW, Germany
Other Locations
Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)
Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)
Enrollment Status: Terminated
Publish Date: October 29, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 3
Phase I/II Study of Sensitization of Non-M3 Acute Myeloid Leukemia (AML) Blasts to All-trans Retinoic Acid (ATRA) by Epigenetic Treatment With Tranylcypromine (TCP), an Inhibitor of the Histone Lysine Demethylase 1 (LSD1)
Phase I/II Study of Sensitization of Non-M3 Acute Myeloid Leukemia (AML) Blasts to All-trans Retinoic Acid (ATRA) by Epigenetic Treatment With Tranylcypromine (TCP), an Inhibitor of the Histone Lysine Demethylase 1 (LSD1)
Enrollment Status: Unknown
Publish Date: October 18, 2018
Intervention Type: Drug
Study Drugs: Tranylcypromine, All-Trans Retinoic Acid, Cytarabine
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

60 Total Publications

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.
Journal: Blood
Published: July 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Bochtler's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile